FDA approves Mimrylo for treatment of polycythemia vera
The U.S. FDA approved Mimrylo, a weekly injection for the treatment of polycythemia vera. The approval provides a new national regulatory option for a rare disease. The drug is newly approved, and its real-world effectiveness and use are not yet demonstrated.
Why it matters
This approval provides a new treatment option for patients with a rare blood cancer, addressing a need for additional therapies.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news